Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on August 14, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Auro Laboratories' Board approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell sharply to Rs. 277.42 lakhs from Rs. 572.04 lakhs in Q1 FY25, a decline of roughly 51%. The company swung to a loss of Rs. 10.55 lakhs at the PAT level, compared to a profit of Rs. 75.27 lakhs in the same quarter last year, resulting in a negative EPS of Rs. 0.17. The statutory auditors (Kothari Jain & Associates) issued an unmodified limited review report with no qualifications. Additionally, the Board accepted the resignation of Company Secretary and Compliance Officer Ms. Priyanka Gupta, effective September 30, 2025, citing better prospects. She had been in the role only since February 14, 2025.
Weak Q1 performance with revenue halving and a swing to loss is a negative signal for short-term sentiment, though the company remains in a single pharmaceuticals segment and Other Equity stands at Rs. 3,673.56 lakhs. The relatively short-tenured Company Secretary's exit is a routine governance item but warrants a watch for timely replacement.